This trial is evaluating whether Radiation - Dose Level 0 will improve 1 primary outcome and 6 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of 1 Month.
This trial requires 30 total participants across 5 different treatment groups
This trial involves 5 different treatments. Radiation - Dose Level 0 is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Data from a recent study of this study indicate that RT-dose levels 0 and ≥ 2 Gy can be administered safely together with other treatments. The good quality of life and excellent survival rate warrant further investigations regarding optimal radiation-dose level using IMRT as well as new methods for early determination of organ toxicity during radiotherapy." - Anonymous Online Contributor
"A cure can be achieved only for certain types of lymphoma, such as non-Hodgkin's lymphoma. It is possible to cure a person with Hodgkin's disease from the disease, but there is no guarantee that the person will remain free of the disease indefinitely. However, some recent studies suggest that Hodgkin's disease may become more manageable over time (i.e., after a period of initial remission). Also, a cure cannot be guaranteed for patients with mantle cell lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, or chronic lymphocytic leukemia." - Anonymous Online Contributor
"Radiation therapy restores tumor destruction in patients with HL, regardless of the stage. In addition, the improvement in tumor control caused by radiation therapy was not associated with significant changes in overall survival or relapse-free survival." - Anonymous Online Contributor
"Radiation therapy is an effective treatment.. Radiation therapy has improved survival over the past 15 years. A definitive link between radiotherapy and HL could not be established. Overall incidence rates of HL have decreased by 42% since 1992." - Anonymous Online Contributor
"A significant number of patients with lymphoma or at risk of developing lymphoma are currently receiving insufficient amounts of timely treatment. There is also a large proportion of people who have not received any therapy for their lymphoma. New therapies continue to be discovered; however, there remains a strong need for effectiveness and safety testing before these new drugs become available to patients. It is estimated that over 90% of patients would benefit from existing therapies if they could be improved to maximize efficacy while minimizing toxic effects." - Anonymous Online Contributor
"Approximately 730 cases per 100,000 persons a year in the U.S. are reported as having lymphoma, based primarily on data obtained from the National Cancer Institute Surveillance Epidemiology and End Results database. These estimates may underestimate the true incidence of lymphoma because they exclude undiagnosed cases and underdiagnose cases that do not produce symptoms. But this underestimation does not substantially change the estimated annual incidence. Because the incidence of lymphoma varies widely by geographic location and socioeconomic status, these estimates should help guide resource allocation in the U.S. and elsewhere." - Anonymous Online Contributor
"More recent studies have shown a correlation between improved outcomes in both localized and advanced-stage disease, as well as among specific subtypes of lymphoma. Although there may be modest differences in survival rates between racial groups, these differences are unlikely to result in disparities in survival. Results from a recent clinical trial are consistent with national data demonstrating that overall survival in lymphoma patients is improving steadily." - Anonymous Online Contributor
"The radiation dose levels prescribed by the Radiation Oncologist and the Radiation Physician in the treatment of patients with HL were very similar. The mean dose to the heart was “low” (below 28 Gy). However, there was a wide range of individual doses that exceeded this criterion. Patients who receive neither target volume nor heart dose above 28 Gy are at significant risk of developing cardiomyopathy as a consequence of radiation exposure." - Anonymous Online Contributor
"Lymphoma is a group of cancers that are caused by uncontrollable growth and proliferation of a abnormal population of white blood cells. These cells are called lymphocytes. The exact definition of lymphoma varies greatly depending upon the country in which a diagnosis is made.\nWell differentiated lymphoma is generally a form of lymphoid leukemia, while poorly differentiated lymphoma is usually a more aggressive subtype of diffuse large B-cell lymphoma. The distinction between well and poorly differentiated forms of lymphoma is blurred. Usually, the poorly differentiated form is more aggressive and can be treated differently than the well differentiated form. However, both types can be treated with chemotherapy, steroids, or radiotherapy." - Anonymous Online Contributor
"There are many signs and symptoms of lymphoma; the severity depends on the type of lymphoma. All patients who present with fever, night sweats, weight loss and/or swelling should be evaluated for possible lymphoma\n" - Anonymous Online Contributor
"Current radiation dose levels encompass a wide range of doses ranging from low levels (<1 Gy) to high levels (>30 Gy). Radiation dose levels>30 Gy may be considered as local radiotherapy for localized HL and high doses (>30 Gy) may be used as systemic therapy for disseminated HL." - Anonymous Online Contributor